Refine by
Biopsy Test Suppliers & Manufacturers
33 companies found
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inFrankfurt, GERMANY
NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer. The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. ...
From the moment melanoma is diagnosed, your patient depends on you to recommend the best course of action. Hovever, it is important to remember that no two melanoma patients or their tumors are alike.The MELAGENIX test provides a genomic-based, ...
based inMenlo Park, CALIFORNIA (USA)
We’re a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. We work to improve disease detection by counting molecules with our proprietary molecular counting platform. We place patients at the forefront ...
Our molecular counting platform can help quantify nearly undetectable DNA changes, unlocking improvements to non-invasive prenatal screening and liquid ...
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay ...
based inNew York, NEW YORK (USA)
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management ...
The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers. The initial test delivered by the miR ...
based inSan Diego, CALIFORNIA (USA)
We are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy. ...
Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine™ from Thermo Fisher Scientific’s next-generation sequencing and decision support ...
based inMarlborough, MASSACHUSETTS (USA)
Cytiva, now with the life sciences business from Pall, is a global provider of technologies, services, and expertise to help researchers and companies protect and preserve the planet for improved human health and safety. Our products offer quality, ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inPleasanton, CALIFORNIA (USA)
Anchor Molecular is a life science diagnostics company specializing in the development of best-in-class quality controls, reference materials, and reagents for liquid biopsy assays. We focus on liquid biopsy cancer diagnostic test based on cell-free ...
based inCleveland, OHIO (USA)
Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. The Company’s Solvent Interaction Analysis ...
IsoPSA Proceed to biopsy only when needed. IsoPSA is now included in NCCN® Prostate Cancer Early Detection Guidelines. IsoPSA can help reduce unnecessary prostate biopsies by up to 55%. Up to 75% of results from ...
based inTrieste, ITALY
Today Eurospital manufactures and commercializes pharmaceutical products, medical-surgical and diagnostic devices and a completely new line of gluten-free products. Throughout the years it extended its range of action by implementing strategic ...
based inPrinceton, NEW JERSEY (USA)
Cysview is a pharmaceutical product that makes non-muscle invasive bladder cancer tumors glow bright pink under blue light during a cystoscopy. Because the cancer is more visible, urologists can remove it more completely than if they weren’t using ...
A Transurethral Resection of Bladder Tumor (TURBT) is a procedure where a urologist removes tumors from the bladder wall. The procedure is performed using specialized instruments that are inserted through the urethra into the bladder. For the tumor ...
based inIrvine, CALIFORNIA (USA)
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on ...
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), ...
based inValladolid, SPAIN
Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies ...
It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT). DiagnoLung identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung ...
based inIrvine, CALIFORNIA (USA)
Established in 2011, Pathnostics is driven to pioneer a better future for physicians, patients, and the healthcare system with solutions that transform diagnostic and therapeutic dilemmas. Core capabilities in infectious disease and cancer ...
The Guidance Pre Prostate Biopsy Rectal Swab (GPPBRS) test identifies antimicrobials that may be used prophylactically by using our patented Pooled-Antimicrobial Susceptibility Testing technology to ...
based inLund, SWEDEN
SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly ...
In direct comparisons, ctDNA has been shown to be superior to conventional serum protein biomarkers, circulating tumor cells, and radiographic imaging. Analysis of ctDNA in liquid biopsies is rapidly becoming one of the most important minimally ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Pioneering Innovation, Streamlining Adoption: We are pushing the boundaries of today’s liquid biopsy capabilities. Bring liquid biopsy to your lab with our streamlined DNA-only NGS workflow, taking you from cell-free DNA sample to ...
based inMunich, GERMANY
ImevaX is a Biotech company based in Munich with a focus on facilitating H. pylori Diagnostics with a novel Rapid Diagnostic ...
based inSouth San Francisco, CALIFORNIA (USA)
Veracyte is a pioneering genomic diagnostics company. Our tests provide trustworthy and actionable ANSWERS that improve care throughout the patient journey. We ask the right questions and provide answers that give physicians and patients a clearer ...
Providing clarity and confidence in treatment planning. The Decipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) genomic classifier is a 22-gene, whole-transcriptome-developed test designed to help ...